Acticor Biotech announced on Monday that the Paris Commercial Court had ordered the company’s compulsory liquidation last Thursday.
“Despite all our efforts over the last few months, we have not succeeded in refinancing the company within the timeframe set by the court-ordered receivership procedure”, explains CEO Dr. Gilles Avenard.
In view of this court decision, Acticor Biotech’s shares will not be listed again, and an application will shortly be made to Euronext to delist them, says the company in a brief press release.
The biotech, which wanted to develop a high-potential…
